- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07537413
Posologie de la ceftriaxone pour la pneumonie acquise en communauté non critique (DC-CAP)
Essai Pragmatique Randomisé Évaluant la Posologie du Ceftriaxone pour la Pneumonie Acquise en Communauté en Dehors de l'Unité de Soins Intensifs
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jonathan D Baghdadi, MD, PhD
- Numéro de téléphone: 410-706-0066
- E-mail: jbaghdadi@som.umaryland.edu
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland Medical Center
-
Contact:
- Megan Dunning, MD
- Numéro de téléphone: 410-328-8667
- E-mail: mdunning@ihv.umaryland.edu
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland Medical Center - Midtown Campus
-
Contact:
- Jonathan Baghdadi, MD, PhD
- Numéro de téléphone: 410-225-8000
- E-mail: jbaghdadi@som.umaryland.edu
-
Glen Burnie, Maryland, États-Unis, 21061
- UM Baltimore Washington Medical Center
-
Contact:
- Stephanie Pires, PharmD
- Numéro de téléphone: 410-787-4000
- E-mail: Stephanie.Pires@umm.edu
-
Towson, Maryland, États-Unis, 21204
- University of Maryland St. Joseph Medical Center
-
Contact:
- Rose Kohinke, PharmD
- Numéro de téléphone: 410-337-1000
- E-mail: Rose.Kohinke@umm.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Exclusion Criteria:
- Planned or present admission to an intensive care unit
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Low Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia. |
|
Comparateur actif: Moderate Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Antibiotic escalation within 5 days of randomization
Délai: The outcome will be assessed 5 days after enrollment
|
Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation |
The outcome will be assessed 5 days after enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to stability
Délai: The outcome will be assessed 90 days after enrollment
|
Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period |
The outcome will be assessed 90 days after enrollment
|
|
Clinical deterioration within 10 days of randomization
Délai: The outcome will be assessed 10 days after enrollment
|
Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter |
The outcome will be assessed 10 days after enrollment
|
|
Ceftriaxone-associated toxicity within 10 days of randomization
Délai: The outcome will be assessed 10 days after enrollment
|
Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology) |
The outcome will be assessed 10 days after enrollment
|
|
Ranked composite outcome
Délai: The outcome will be assessed 30 days after enrollment
|
Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality |
The outcome will be assessed 30 days after enrollment
|
|
Duration of antibiotics
Délai: The outcome will be assessed 90 days after enrollment
|
Defined as the total days of antibiotic therapy during the hospital encounter |
The outcome will be assessed 90 days after enrollment
|
|
Hospital length of stay
Délai: The outcome will be assessed 90 days after enrollment
|
Duration of hospitalization in days |
The outcome will be assessed 90 days after enrollment
|
|
All-cause readmission
Délai: The outcome will be assessed 90 days from enrollment
|
Readmission for any reason within 30 days of hospital discharge |
The outcome will be assessed 90 days from enrollment
|
|
In-hospital mortality
Délai: The outcome will be assessed 90 days after enrollment
|
In-hospital death or discharge to hospice |
The outcome will be assessed 90 days after enrollment
|
|
Clostridioides difficile infection
Délai: The outcome will be assessed 90 days after enrollment
|
Positive laboratory test for Clostridioides difficile within 30 days of randomization |
The outcome will be assessed 90 days after enrollment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HP-00117776
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .